Destabilizing missense mutations in the tumour suppressor …
WEBJul 7, 2006 · This has implications for understanding the recognition of misfolded proteins during aging and in human diseases such as cancer. Keywords: chaperone, murine double minute clone 2 oncoprotein (MDM2), p53, protein folding, ubiquitin.
Lee FINLAN | Research profile
WEBEpidermal stem cells and cancer stem cells: Insights into cancer and potential therapeutic strategies
p63: the phantom of the tumor suppressor - PubMed
WEBMay 2, 2007 · Is p63 required to provide cancer cell populations with a selective advantage as much as a loss of p53 function by mutation? Has p53 been masking a "phantom" with promising features as a target for drug development?
Destabilizing missense mutations in the tumour suppressor …
WEBThese data identify an in vitro and in vivo assay with which to dissect how oligomeric protein conformational alterations are linked to substrate ubiquitination in cells. This has implications for understanding the recognition of misfolded proteins during aging and in human diseases such as cancer.
Destabilizing missense mutations in the tumour suppressor …
WEBJun 28, 2006 · This has implications for understanding the recognition of misfolded proteins during aging and in human diseases such as cancer.
The N-terminal interferon-binding domain (IBiD) homology …
WEBLee Finlan, Ted R Hupp. ... Edinburgh Cancer Research Centre; Research output: Contribution to journal › Article › peer-review. Overview; Fingerprint; Abstract. Two high affinity Ser-20-phospho-LXXLL p53-binding domains of p300 map to the C-terminal interferon-binding domain (IBiD) and N-terminal IBiD …
Lee Finlan - PhD on LinkedIn: FDA Approval Sought for Frontline ...
WEB1,184,795 followers. 7mo. Today Amgen announced new CodeBreaK 101 clinical trial data for its KRASG12C inhibitor used in combination with chemotherapy in the treatment of KRAS G12C-mutated advanced...
Lee Finlan - PhD’s Post - LinkedIn
WEBFDA Approval Sought for Fruquintinib in Refractory Metastatic Colorectal Cancer Treatment
WEBTwo distinct synthetic Lee Finlan1 CDK1/2 inhibitors, Roscovitine and NU2058, are pharmacologically distinct in their Elaine M. Rankin2 ability to modify p53-dependent transcription and perturb cell cycle progression. Ibbotson3. Although such active-site CDK1/2 inhibitors comprise the most standard type of enzyme.
WEBaging and in human diseases such as cancer. Keywords:chaperone,murinedoubleminuteclone2oncoprotein (MDM2), p53, protein folding, ubiquitin. INTRODUCTION
Skip to content